{
  "id": 185791,
  "title": "Soriot should explain the curious case of AstraZeneca’s non-deal",
  "url": "https://urgent.news/2026/08/05/soriot-should-explain-the-curious-case-of-astrazenecas-non-deal",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-05T17:45:05.000Z",
  "source": {
    "name": "Guardian Business",
    "slug": "guardian-business",
    "url": "https://www.theguardian.com/business/nils-pratley-on-finance/2026/aug/05/soriot-should-explain-the-curious-case-of-astrazenecas-non-deal"
  },
  "original_language": "en",
  "account": null,
  "summary": "AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders AstraZeneca falls to third-largest UK company amid US merger talks Hold the heartburn pills. It seems AstraZeneca is no longer contemplating a takeover of US rival Bristol Myers Squibb (BMS) to create a $400bn (£300bn) pharmaceutical colossus . On Monday, the UK…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}